These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34563653)

  • 1. Molecular dynamics study of enhanced autophosphorylation by S904F mutation of the RET kinase domain.
    Chen YJ; Li PY; Yang CN
    J Struct Biol; 2021 Dec; 213(4):107799. PubMed ID: 34563653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans.
    Plaza-Menacho I; Barnouin K; Goodman K; Martínez-Torres RJ; Borg A; Murray-Rust J; Mouilleron S; Knowles P; McDonald NQ
    Mol Cell; 2014 Mar; 53(5):738-51. PubMed ID: 24560924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A secondary RET mutation in the activation loop conferring resistance to vandetanib.
    Nakaoku T; Kohno T; Araki M; Niho S; Chauhan R; Knowles PP; Tsuchihara K; Matsumoto S; Shimada Y; Mimaki S; Ishii G; Ichikawa H; Nagatoishi S; Tsumoto K; Okuno Y; Yoh K; McDonald NQ; Goto K
    Nat Commun; 2018 Feb; 9(1):625. PubMed ID: 29434222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.
    Dixit A; Torkamani A; Schork NJ; Verkhivker G
    Biophys J; 2009 Feb; 96(3):858-74. PubMed ID: 19186126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
    Terzyan SS; Shen T; Liu X; Huang Q; Teng P; Zhou M; Hilberg F; Cai J; Mooers BHM; Wu J
    J Biol Chem; 2019 Jul; 294(27):10428-10437. PubMed ID: 31118272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach.
    George Priya Doss C; Rajith B; Chakraboty C; Balaji V; Magesh R; Gowthami B; Menon S; Swati M; Trivedi M; Paul J; Vasan R; Das M
    Mol Biosyst; 2014 Mar; 10(3):421-36. PubMed ID: 24336963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure and chemical inhibition of the RET tyrosine kinase domain.
    Knowles PP; Murray-Rust J; Kjaer S; Scott RP; Hanrahan S; Santoro M; Ibáñez CF; McDonald NQ
    J Biol Chem; 2006 Nov; 281(44):33577-87. PubMed ID: 16928683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and dynamic determinants for highly selective RET kinase inhibition reveal cryptic druggability.
    Shehata MA; Contreras J; Martín-Hurtado A; Froux A; Mohamed HT; El-Sherif AA; Plaza-Menacho I
    J Adv Res; 2023 Mar; 45():87-100. PubMed ID: 35595215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.
    Cao S; Tan C; Fei A; Hu G; Fu M; Lv J
    J Mol Model; 2022 Dec; 29(1):24. PubMed ID: 36576611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic mechanism for the autophosphorylation of CheA histidine kinase: molecular dynamics simulations.
    Zhang J; Xu Y; Shen J; Luo X; Chen J; Chen K; Zhu W; Jiang H
    J Am Chem Soc; 2005 Aug; 127(33):11709-19. PubMed ID: 16104748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements.
    Plaza-Menacho I; Barnouin K; Barry R; Borg A; Orme M; Chauhan R; Mouilleron S; Martínez-Torres RJ; Meier P; McDonald NQ
    Cell Rep; 2016 Dec; 17(12):3319-3332. PubMed ID: 28009299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cocrystallization of the Src-Family Kinase Hck with the ATP-Site Inhibitor A-419259 Stabilizes an Extended Activation Loop Conformation.
    Selzer AM; Alvarado JJ; Smithgall TE
    Biochemistry; 2024 Oct; 63(20):2594-2601. PubMed ID: 39315638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.
    Gao C; Grøtli M; Eriksson LA
    J Mol Model; 2015 Jul; 21(7):167. PubMed ID: 26044359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How does nintedanib overcome cancer drug-resistant mutation of RET protein-tyrosine kinase: insights from molecular dynamics simulations.
    Cao S; Jiang X; Tan C; Fu M; Xiong W; Ji D; Lv J
    J Mol Model; 2021 Nov; 27(11):337. PubMed ID: 34725737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
    Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
    Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Peutz-Jeghers syndrome (PJS) causing missense mutations L67P, L182P, G242V and R297S on the structural dynamics of LKB1 (Liver kinase B1) protein.
    Rungsung I; Ramaswamy A
    J Biomol Struct Dyn; 2019 Feb; 37(3):796-810. PubMed ID: 29447078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.
    Moccia M; Liu Q; Guida T; Federico G; Brescia A; Zhao Z; Choi HG; Deng X; Tan L; Wang J; Billaud M; Gray NS; Carlomagno F; Santoro M
    PLoS One; 2015; 10(6):e0128364. PubMed ID: 26046350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B.
    Gujral TS; Singh VK; Jia Z; Mulligan LM
    Cancer Res; 2006 Nov; 66(22):10741-9. PubMed ID: 17108110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.
    Liu Z; Galemmo RA; Fraser KB; Moehle MS; Sen S; Volpicelli-Daley LA; DeLucas LJ; Ross LJ; Valiyaveettil J; Moukha-Chafiq O; Pathak AK; Ananthan S; Kezar H; White EL; Gupta V; Maddry JA; Suto MJ; West AB
    J Biol Chem; 2014 Nov; 289(47):32937-51. PubMed ID: 25228699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.